glp-1 moa Receptor Agonists as Treatments for Type 2 Diabetes GLP1 Receptor Agonists—Effects beyond Obesity

As healthcare systems prioritize chronic disease management, GLP-1 receptor agonists are positioned to remain a critical component of treatment protocols

While these earlier drugs demonstrated the potential of GLP-1 therapy, the newer medications semaglutide, tirzepatide, and retatrutide have completely changed the game

FehmannHCHeringBJWolfMJBrandhorstHBrandhorstDBretzelRGet al

This structured screening ensures that only appropriate candidates receive therapy and that monitoring is in place where risks are identified

Rising prevalence of type 2 diabetes mellitus Shift toward non-insulin therapies Advancements in drug delivery technologies Growing patient awareness and cultural shifts in obesity management High treatment costs Adverse effects and contraindications This substantial growth is driven by the rising prevalence of type 2 diabetes mellitus, a shift toward non-insulin therapies, advancements in drug delivery technologies, and cardiovascular and weight management benefits

In terms of side effects and tolerability, the advantage goes to neither (comparable)